Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Cancer Chemotherapy and Pharmacology
Journal
Overview
Identity
Overview
Publication Venue For
Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors
. 83:551-559.
2019
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer
. 81:413-417.
2018
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
. 80:1209-1217.
2017
DNA topoisomerase-targeting chemotherapeutics: what’s new?
. 80.
2017
Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients
. 78:509-515.
2016
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC)
. 76:949-955.
2015
Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: Remission and lack of host toxicity
. 69:1449-1455.
2012
Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias
. 68:399-403.
2011
A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer
. 67:891-897.
2011
Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity
. 62:85-96.
2008
Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor
. 58:692-698.
2006
5-(Phenylthio)acyclouridine: A powerful enhancer of oral uridine bioavailability: Relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens
. 55:541-551.
2005
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models
. 55:411-419.
2005
Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines
. 54:71-78.
2004
Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer
. 52:399-404.
2003
Preclinical antitumor activity of 4′-thio-β-D-arabinofuranosylcytosine (4′-thio-ara-C)
. 51:422-426.
2003
Synergistic cytotoxic effect between serine-threonine phosphatase inhibitors and 5-fluorouracil: A novel concept for modulation of cytotoxic effect
. 49:111-118.
2002
Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: Implications for uridine rescue regimens in chemotherapy
. 48:389-397.
2001
Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: Implications for chemotherapy
. 48:145-150.
2001
Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2', 3', 5'-tri-O-acetyluridine, a prodrug of uridine: Relevance to uridine rescue in chemotherapy
. 46:235-240.
2000
Modulation of plasma uridine concentration by 5- (phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: Relevance to chemotherapy
. 45:351-361.
2000
Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma
. 46:173-179.
2000
Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I
. 41:257-267.
1998
Etoposide sensitivity of radioresistant human glioma cell lines
. 41:93-97.
1997
Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion
. 40:376-384.
1997
The significance of the sequence of administration of topotecan and etoposide
. 39:109-112.
1996
Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy
. 37:14-22.
1995
Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer
. 33:472-476.
1994
Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin
. 34.
1994
2,4-Diamino-6-(bis-2-chloroethyl)aminomethyl pteridine - A new potent anticancer drug
. 13:73-74.
1984
Identity
International Standard Serial Number (issn)
0344-5704
Electronic International Standard Serial Number (eissn)
1432-0843